<DOC>
	<DOC>NCT00429936</DOC>
	<brief_summary>The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).</brief_summary>
	<brief_title>Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>males or females, 50 to 89 years of age must have GA from AMD in one or both eyes GA due to any disease other than AMD (eg, druginduced)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Dry Age Related Macular Degeneration</keyword>
	<keyword>Geographic Atrophy</keyword>
</DOC>